--- title: "【Corporate Earnings Surprise】SIHUAN PHARM is expected to turn a loss into a profit of no less than 150 million yuan last year" type: "News" locale: "en" url: "https://longbridge.com/en/news/275530668.md" description: "SIHUAN PHARM expects its annual net profit for the year ended December 31 last year to be no less than RMB 150 million, an improvement compared to a loss of RMB 200 million in 2024. Revenue is expected to exceed RMB 2.5 billion, with growth of over 30%. The turnaround from loss to profit is mainly attributed to significant growth in the medical aesthetics business and innovative drug business. The group plans to announce its performance by the end of March" datetime: "2026-02-11T00:41:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275530668.md) - [en](https://longbridge.com/en/news/275530668.md) - [zh-HK](https://longbridge.com/zh-HK/news/275530668.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275530668.md) | [繁體中文](https://longbridge.com/zh-HK/news/275530668.md) # 【Corporate Earnings Surprise】SIHUAN PHARM is expected to turn a loss into a profit of no less than 150 million yuan last year According to a report from Economic News Agency on the 11th, SIHUAN PHARM (00460) announced that it expects net profit for the year ending December 31 last year to be no less than 150 million yuan (RMB, same below), with a loss of 200 million yuan in 2024. The group indicated that it expects revenue to be no less than 2.5 billion yuan, an increase of over 30%. The turnaround to profitability is due to medical beauty business revenue exceeding 1.4 billion yuan and segment profits exceeding 700 million yuan, both rising by more than 90%. The innovative drug business has entered a harvest period, with significant revenue growth from XuanZhu Biotechnology-B (02575) and Huisheng Biotechnology, as well as the completion of the spin-off listing of XuanZhu Biotechnology, resulting in significant equity appreciation gains. The group expects to announce its performance by the end of March. (wh) ### Related Stocks - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/en/quote/159615.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/en/quote/588860.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/en/quote/560600.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/en/quote/513700.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/en/quote/516820.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/en/quote/513060.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/en/quote/159506.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/en/quote/159859.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/en/quote/588250.CN.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/en/quote/159102.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md) - [SIHUAN PHARM (00460.HK)](https://longbridge.com/en/quote/00460.HK.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/en/quote/159892.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md) ## Related News & Research - [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/en/news/281662341.md) - [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/en/news/281054154.md) - [ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma](https://longbridge.com/en/news/281068292.md) - [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/en/news/281501537.md) - [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/en/news/281231901.md)